Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 18, 2014 - Issue 9
Submit an article Journal homepage
1,066
Views
7
CrossRef citations to date
0
Altmetric
Editorial

Looking for a new panacea in ALK-rearranged NSCLC: may be Ceritinib?

Christian RolfoAntwerp University Hospital, Oncology Department, Phase I-Early Clinical Trials Unit, Wilrijkstraat 10, 2650 Edegem, Belgium+3238213646; +3238251592; [email protected]
, MD PhD MBAH,
Francesco PassigliaAntwerp University Hospital, Oncology Department, Phase I-Early Clinical Trials Unit, Wilrijkstraat 10, 2650 Edegem, Belgium;Palermo University Hospital, Department of Surgical, Oncological and Oral Sciences, Via del Vespro, 129, Palermo, 90127, Italy
, MD,
Antonio RussoPalermo University Hospital, Department of Surgical, Oncological and Oral Sciences, Via del Vespro, 129, Palermo, 90127, Italy
, MD PhD &
Patrick PauwelsAntwerp University Hospital, Pathology Department, Molecular Pathology Unit, Wilrijkstraat, 10, 2650 Edegem, Belgium
, MD PhD
Pages 983-985 | Published online: 05 Jul 2014

Bibliography

  • Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27:4247-53
  • Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6
  • Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012;13:1011-19
  • Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94
  • Mok T, Kim DW, Wu YL, et al. First-line crizotinib versus pemetrexed–cisplatin or pemetrexed– carboplatin in patients (pts) with advancedALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014). J Clin Oncol 2014;32:5s
  • Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med 2012;4:120ra117
  • Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012;18:1472-82
  • Rolfo C, Passiglia F, Castiglia M, et al. ALK and crizotinib: after the honeymoon… what else? Resistance mechanisms and new therapies to overcome it. Transl Lung Cancer Res 2014. doi: 10.3978/j.issn.2218-6751.2014.03.01
  • Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014;370:1189-97
  • Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 2014;4:662-73

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.